The Stanford Cancer Institute Early Drug Development Program (EDD), led by Christopher Chen, MD, aims to advance cancer treatment through early-phase clinical trials for solid tumors. It offers patients access to innovative therapies that extend beyond standard treatments and conducts research to determine the safety and efficacy of new drugs.

The program operates in a multidisciplinary environment, fostering collaboration among medical oncologists, advanced practice providers, nurses, pharmacists, clinical research coordinators, social workers, and medical assistants. Together, the team delivers exceptional and safe patient care while paving the way for effective treatment options for future patients.

The Early Drug Development Program seeks to:

• Offer patients early access to cutting-edge therapies for solid tumors.
• Contribute to the research and development of new treatments by determining safe, effective dosing for future phase II and III trials.
• Accelerate the assessment of promising drugs through innovative clinical trial designs.